| __timestamp | Apellis Pharmaceuticals, Inc. | Bristol-Myers Squibb Company |
|---|---|---|
| Wednesday, January 1, 2014 | 2908166 | 5699000000 |
| Thursday, January 1, 2015 | 6356782 | 5001000000 |
| Friday, January 1, 2016 | 4303743 | 5002000000 |
| Sunday, January 1, 2017 | 10463151 | 4849000000 |
| Monday, January 1, 2018 | 22639184 | 4551000000 |
| Tuesday, January 1, 2019 | 67046483 | 4871000000 |
| Wednesday, January 1, 2020 | 139401000 | 7661000000 |
| Friday, January 1, 2021 | 176771000 | 7690000000 |
| Saturday, January 1, 2022 | 277163000 | 7814000000 |
| Sunday, January 1, 2023 | 500815000 | 7772000000 |
| Monday, January 1, 2024 | 8414000000 |
In pursuit of knowledge
In the competitive landscape of the pharmaceutical industry, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Bristol-Myers Squibb Company and Apellis Pharmaceuticals, Inc. have demonstrated contrasting approaches to SG&A efficiency.
Bristol-Myers Squibb, a stalwart in the industry, consistently maintained high SG&A expenses, peaking at approximately $7.8 billion in 2022. This reflects their expansive operations and robust market presence. In contrast, Apellis Pharmaceuticals, a relatively newer player, showed a dramatic increase in SG&A expenses, skyrocketing from a modest $2.9 million in 2014 to over $500 million by 2023. This 17,000% increase underscores their aggressive growth strategy and market penetration efforts.
Understanding these trends offers valuable insights into how established giants and emerging innovators navigate financial strategies in the ever-evolving pharmaceutical sector.
Operational Costs Compared: SG&A Analysis of Johnson & Johnson and Bristol-Myers Squibb Company
Amgen Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Bristol-Myers Squibb Company or Zoetis Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Bristol-Myers Squibb Company vs Supernus Pharmaceuticals, Inc.
Halozyme Therapeutics, Inc. and Apellis Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Ultragenyx Pharmaceutical Inc. vs Apellis Pharmaceuticals, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: Apellis Pharmaceuticals, Inc. vs Ligand Pharmaceuticals Incorporated
Cost Management Insights: SG&A Expenses for Apellis Pharmaceuticals, Inc. and Iovance Biotherapeutics, Inc.
Comparing SG&A Expenses: Apellis Pharmaceuticals, Inc. vs Wave Life Sciences Ltd. Trends and Insights